<DOC>
	<DOC>NCT01737931</DOC>
	<brief_summary>To investigate the efficacy of symptomatic therapy with topical steroids and antihistamines for application site reaction (ASR) after administration of SPM 962 in healthy subjects</brief_summary>
	<brief_title>A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject</brief_title>
	<detailed_description />
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<criteria>Subject is a male or female and aged between 20 and 45 years of age (inclusive) Subject is of normal body weight as determined by a bodymass index (BMI) between 18 and 28 kg/m2 Subject is healthy as determined by EA (medical history, physical examination, skin evaluation, vital signs, ECG, hematology, clinical chemistry, urinalysis) Subject is surgically sterile; subject has been postmenopausal for at least 12 consecutive months if female; or subject agrees to remain abstinent or to follow two acceptable methods of birth control from EA to the end of observation period. (fore male and female subjects) Subject has a history or complication of epilepsy and/or seizures Subject has clinically relevant changes in the ECG, such as second or thirddegree AV block, a complete bundle branch block, prolongation of the QRS complex over 120 ms, or of the QTcB (QT interval corrected for HR by BazettÂ´s formula) over 500 ms at EA Subject has a clinically relevant hepatic dysfunction Subject has a clinically relevant renal dysfunction Subject has a history of significant skin hypersensitivity to adhesives or other transdermal products or recent unresolved contact dermatitis Subject has a history or complication of atopic or eczematous dermatitis, psoriasis, and/or an active skin disease or skin tumors Subject has more than 1 known or suspected drug hypersensitivity, in particular to any component of the trial medication Subject has a history of chronic alcohol or drug abuse within the last 5 years Subject is tested positive for HIV1/2Ab, HBsAg or HCVAb Subject tests positive for alcohol and/or drugs at EA Subject is taking any prohibited concomitant medication Subject has a history or complication of narrow angle glaucoma Subject has a history or complication of respiratory or cardiovascular disorders (e.g., heart failure, coronary heart disease, hypertension, arrhythmia, tachyarrhythmia, or myocardial infarction) Subject has a history or complication of psychic abnormality, psychiatric or neurologic illness, or autonomic neuropathy Subject has a history or complication of diabetes mellitus and/or thyroid dysfunction, especially hyperthyroidism or other endocrine disorders Subject has a history or complication of malignancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>SPM 962</keyword>
	<keyword>rotigotine</keyword>
	<keyword>application site reaction</keyword>
</DOC>